Antidiarrheal Prophylaxis Optimizes Neratinib Use in HER2+ Breast Cancer

Caroline Seymour
Published: Tuesday, May 07, 2019
Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD

Early prophylactic interventions have offset initial concerns regarding the incidence and severity of neratinib (Nerlynx)-associated diarrhea seen in the ExteNET trial, explained Martin Dietrich, MD, PhD, giving patients with HER2-positive breast cancer at high risk of recurrence a better chance of completing the full 1 year of extended adjuvant therapy and reducing their risk of developing invasive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x